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Abstract
Background: Autosomal dominant polycystic kidney disease (ADPKD) causes progressive loss of renal function in
adults as a consequence of the accumulation of cysts. ADPKD is the most common genetic cause of end-stage
renal disease. Mutations in polycystin-1 occur in 87% of cases of ADPKD and mutations in polycystin-2 are found in
12% of ADPKD patients. The complexity of ADPKD has hampered efforts to identify the mechanisms underlying its
pathogenesis. No current FDA (Federal Drug Administration)-approved therapies ameliorate ADPKD progression.
Results: We used the de Almeida laboratory’s sensitive new transcriptogram method for whole-genome gene
expression data analysis to analyze microarray data from cell lines developed from cell isolates of normal kidney
and of both non-cystic nephrons and cysts from the kidney of a patient with ADPKD. We compared results
obtained using standard Ingenuity Volcano plot analysis, Gene Set Enrichment Analysis (GSEA) and transcriptogram
analysis. Transcriptogram analysis confirmed the findings of Ingenuity, GSEA, and published analysis of ADPKD
kidney data and also identified multiple new expression changes in KEGG (Kyoto Encyclopedia of Genes and
Genomes) pathways related to cell growth, cell death, genetic information processing, nucleotide metabolism,
signal transduction, immune response, response to stimulus, cellular processes, ion homeostasis and transport and
cofactors, vitamins, amino acids, energy, carbohydrates, drugs, lipids, and glycans. Transcriptogram analysis also
provides significance metrics which allow us to prioritize further study of these pathways.
Conclusions: Transcriptogram analysis identifies novel pathways altered in ADPKD, providing new avenues to
identify both ADPKD’s mechanisms of pathogenesis and pharmaceutical targets to ameliorate the progression of
the disease.
Keywords: Kidney, Transcriptogram, Cystic kidney disease, Autosomal dominant polycystic kidney disease,
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Background
Autosomal dominant polycystic kidney disease (ADPKD)
is a monogenic disorder associated with cystic renal dis-
ease, liver cysts, cardiac valve abnormalities, and berry
aneurysms [1]. Progressive accumulation of renal cysts
in ADPKD culminates in kidney failure, usually during
the fifth or sixth decades of life. With a disease incidence
of 1 in 800, ADPKD is one of the most common human
genetic disorders. Despite extensive research, no Federal
Drug Administration (FDA)-approved treatments prevent
or delay disease progression, limiting patient treatment
options to dialysis or kidney transplantation [2].
Two gene loci are responsible for ADPKD; HmPKD1
(human polycystic kidney disease gene 1) and HmPKD2
(human polycystic kidney disease gene 2) located on
chromosomes 16 and 4, respectively. The gene products
of these loci are polycystin-1 (PC-1) and polycystin-2
(PC-2), proteins that form a heteromeric complex in
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primary cilium of renal cells [3–5]. Primary cilia are
mechanically sensitive and serve as a flow sensor in renal
tubular epithelia [6]. Due to the subcellular localization of
polycystins, and the pleiotropic phenotypes associated
with their mutations, Hildebrandt et al. called ADPKD the
grandfather of ciliopathies [7].
Since ADPKD perturbs the Jnk/Stat (cJun N-terminal
kinases/signal transducer and activator of transcription 1),
MAPK (mitogen-activated protein kinase), mTOR
(mammalian target of rapamycin), Wnt/Wgless (Wing-
less-related integration site/Wingless)and Erk (extracel-
lular signal regulated kinase) kinase pathways [8],
somatostatin analogues, vasopressin receptor antagonists,
mTOR inhibitors, and statins have been tested for their
ability to ameliorate the course of ADPKD. While mTOR
inhibitors reduced cyst growth in murine polycystic kid-
ney disease (PKD) models, they did not slow progression
of renal impairment in human trials [9–11]. The FDA did
not approve a recent vasopressin receptor antagonist,
which inhibited cyst growth in several animal models of
polycystic kidney disease, and slowed increases in total
kidney volume and decreased estimated creatinine clear-
ance in humans [12–14]. Because cyst formation in
ADPKD begins in utero, drugs that can prevent initial cyst
formation are not likely to be acceptable in a clinical set-
ting [15, 16]. However, it is possible that the signaling
pathways that initially drive cyst emergence are the unique
entry points for treatment. We therefore concentrate on
identifying the properties of ADPKD cells derived from
normal nephrons and cysts from the same kidney to
compare to kidney cells derived from an end-stage cystic
kidney and normal human renal cortex. Our eventual
goal would be to identify signaling pathways that provide
a unique opening for targeted therapy in ADPKD.
The paucity of ADPKD drug candidates partially results
from the difficulty in identifying pathways that promote
cyst growth in renal cells but are not essential in other
adult cell types. Standard gene-chip analysis of expressed
mRNA shows that ADPKD perturbs Wnt/Wgless and
Notch signaling [17, 18]. Decreased Notch signaling and
mutated components in the Wnt pathway can cause renal
cystic disease [18–20]. However, the Wnt/Wgless and
Notch signaling pathways are essential to cell fate transi-
tions and assignments in most cell types [21], so targeting
these pathways would likely result in widespread and
damaging bystander effects. Similarly, renal epithelial cells
with an HmPKD1 mutation express many markers of
immature cell differentiation, including increased prolifer-
ation rates, altered cell-ECM (extracellular matrix) adhe-
sion, and increased apoptosis. However, most of these
pathways are ubiquitous and thus not promising drug tar-
gets. To identify promising therapeutic targets, we need to
compare expression patterns in cells from normal human
renal cortex, normal nephrons in ADPKD patents, and in
cysts from the same patients to identify pathways uniquely
active in cystogenesis and not essential in other adult
tissues. Identifying optimal drug targets also requires a
coherent biological context that connects clusters of
gene perturbations to the mechanisms of cyst forma-
tion, not just identification of individual perturbed
genes in cystic ADPKD cells.
The de Almeida laboratory developed transcriptogram
whole-genome gene expression data analysis to identify
perturbed molecular networks and pathways more sensi-
tively than conventional gene-chip analysis methods
[22–24]. Transcriptogram analysis orders genes into a
list using a Monte Carlo simulation that minimizes the
distance within the list between associated gene prod-
ucts, so proximity in the list correlates with the degree
of co-participation in biological processes. Calculating
the average transcription level for genes within a moving
window produces a transcriptogram profile which re-
veals any differentially expressed pathways. This robust
statistical approach couples enhanced significance
assessment with assessment of false discovery rates
(FDRs). Transcriptogram analysis identifies rich sets of
biological signaling interactions for later integrated hy-
pothesis testing.
Results and discussion
We generated three different telomerase-immortalized
cell lines, derived from isolates of (i) a normal kidney of
a 57-year-old male (designated as normal cells, NK), (ii)
non-cystic tissue from the kidney of a 36-year-old male
(designated as non-cystic ADPKD cells, NC-ADPKD),
and (iii) cystic tissue from the same donor (designated
as cystic ADPKD cells, C-ADPKD). The additional
ADPKD cell line in this paper is a previously characterized
telomerase immortalized cell line isolated from an end-
stage polycystic kidney [25]. We refer to the expression
patterns of the NK cells as normal. We refer to expression
of a gene or pathway in ADPKD, NC-ADPKD, or C-
ADPKD cells as higher-than-normal if the expression level
in those cells is significantly greater than in NK cells. Con-
versely, we refer to expression of a gene or pathway in
ADPKD, NC-ADPKD, or C-ADPKD cells as lower-than-
normal if the expression level in those cells is significantly
lower than in NK cells. Differences between the NC-
ADPKD and NK cells are particularly significant because
they may identify early changes permissive for cyst forma-
tion in morphologically normal kidney tissue. We ob-
tained microarray data for genome-wide gene expression
for all cell lines in triplicate. We then analyzed the result-
ing data using three different, complementary methods:
single gene expression analysis using QIAGEN’s Ingenuity
Pathway Analysis (IPA QIAGEN Redwood City), Gene Set
Enrichment Analysis (GSEA) [26], and the transcripto-
gram method [22, 23, 27].
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Mouse and human renal cells with aberrant
polycystin-1 have impaired ciliary mechanosensation,
and this impairment has been proposed as a cellular
mechanism that promotes cystogenesis [28]. How-
ever, most cyst epithelia of human ADPKD kidneys
express full-length polycystin-1 (PC-1) and
polycystin-2 (PC-2) at normal or increased abun-
dance [29–31]. Our PC-1 microarray data agrees
with these observations (Fig. 1). Our microarray data
show equal expression of PC-2 in NC-ADPKD and
NK cells and reduced expression in C-ADPKD cells,
a finding of uncertain significance.
Volcano plots: single-gene analyses
Ingenuity pathway analysis scores each gene independ-
ently to create a list of all genes which change signifi-
cantly in expression between two states. We averaged
gene expression levels over the replicates for each cell
line after normalization and compared cell lines by cal-
culating the fold change (FC) as the ratio between the
averages. We also obtained P values for each gene
expressed. We present the results as Volcano plots
(Fig. 2). Setting a significance threshold of FC > 2 and
P < 0.01, we found 80 genes with significantly altered
expression levels between the NK and NC-ADPKD
cells, 968 genes with significantly altered expression
levels between the NK and C-ADPKD cells, and 1182
genes with significantly altered expression levels be-
tween the C-ADPKD and NC-ADPKD cells (Additional
file 1). These long lists of differentially expressed genes,
by themselves, do not provide immediate insights into
the biological mechanisms of ADPKD.
GSEA: Gene Set Enrichment Analyses
GSEA determines whether an a priori defined set of genes
shows statistically significant, concordant differences be-
tween two biological states [26, 32, 33]. GSEA evaluates
genome-wide expression profiles from cells belonging to
two classes. We performed GSEA on the three pairs: NK
versus NC-ADPKD cells, NK versus C-ADPKD cells, and
NC-ADPKD versus C-ADPKD cells to identify differential
expression in Kyoto Encyclopedia of Genes and Genomes
(KEGG) pathways and in Gene Ontology: Biological
Process (GO) terms. We set a significance threshold for
the gene set permutation FDR <0.05. Table 1 summarizes
the GSEA results and Table 2 lists all significantly altered
KEGG pathway and GO term gene sets.
All GSEA-detected pathway differences between NK
and NC-ADPKD cells related to ‘metabolism’ (We will
use single ‘’ to identify terms from GO and KEGG).
GSEA-detected pathway differences between NK and C-
ADPKD cells relate to ‘chemokine signaling,’ ‘cell migra-
tion,’ and ‘cell-cell adhesion,’ but not ‘metabolism’. GSEA-
detected pathway differences between NC-ADPKD and
C-ADPKD cells relate to ‘chemokine signaling,’ ‘cell migra-
tion,’ and ‘cell-cell adhesion’ but not ‘metabolism’. How-
ever, transcriptogram analyses (see below) show that
expression of metabolome genes differs between these
pairs as well, but too weakly for GSEA to detect, likely
due to the competitive character of GSEA analysis [33].
Transcriptograms: genome-wide landscapes of gene
expression
Transcriptograms project expression profiles onto a gene
list that is ordered with genes belonging to the same
KEGG pathway or GO term clustered in the list. We
built an ordered list of 9684 genes (Additional file 2)
Fig. 1 PKD1 and PKD2 gene expression in the NK, NC-ADPKD,
and C-ADPKD cells. PKD1 expression is not different from normal
in the NC-ADPKD and C-ADPKD cells. PKD2 expression is normal
in the NC-ADPKD cells but significantly lower than normal in
C-ADPKD cells. Bars show mean ± s.e., * * p < 0.01, * p < 0.05
(black asterisk is in comparison to NK, gray asterisk is in
comparison to NC-ADPKD)
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using a Monte Carlo Simulation that minimizes dis-
tances between associated gene products. Specifically,
proximity in the list correlates with co-participation in
biological processes, based on protein-protein associ-
ation information available from the STRING database
[34, 35]. Transcriptogram values then correspond to the
average expression level of the genes located in a window
of radius r = 30 (window size 2r + 1 = 61) along the
ordered list. Overlay of selected GO terms and KEGG
pathways onto the ordered list then serves as a key to the
biological correlates of expression differences and thus
aids interpretation of transcriptograms of experimental
Fig. 2 Volcano plot of single gene analysis. Plots of log P value versus log2 fold change for NC-ADPKD/NK, C-ADPKD/NK, and NC-ADPKD/C-ADPKD
cells. The two vertical lines in each panel mark twofold change. Labels indicate representative genes with highly significant fold changes. See Additional
file 1 for full lists of significantly changed genes
Table 1 GSEA analysis summary
GSEA summary for NC-ADPKD/NK
Upregulated in # gene sets FDR < 0.25 FDR < 0.05 P < 0.05 P < 0.01
NK KEGG 162 15 5 11 7
GOBP 467 0 0 6 1
NC-ADPKD KEGG 162 0 0 20 3
GOBP 467 10 0 41 18
GSEA summary for C-ADPKD/NK
Upregulated in # gene sets FDR < 0.25 FDR < 0.05 P < 0.05 P < 0.01
NK KEGG 162 2 0 8 0
GOBP 467 0 0 11 2
C-ADPKD KEGG 162 15 3 17 12
GOBP 467 1 1 46 13
GSEA summary for NC-ADPKD/C-ADPKD
Upregulated in # gene sets FDR < 0.25 FDR < 0.05 P < 0.05 P < 0.01
NC-ADPKD KEGG 162 11 0 10 4
GOBP 467 17 0 24 13
C-ADPKD KEGG 162 11 4 18 10
GOBP 467 3 1 42 15
Numbers of gene sets that reach significance in comparisons of two GSEA classes, FDR < 0.05, are bold. FDR false discovery rate, P nominal P value, as described
by Subramanian et al. 2005 [26]. GSEA expresses all differences as upregulation to minimize class bias due to the intrinsic asymmetry of the method
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gene expression data (Fig. 3). The x-axis corresponds to
the ordered gene list. Peaks represent regions of the list
enriched with genes belonging to specific pathways or
terms. We normalize the density profiles of term enrich-
ment so that when all genes within a window participate
in that pathway or term, the center point of that interval
has a value of one. This paper presents transcriptograms
as three-part panels, with the transcriptogram itself in the
upper third of the panel, the P values for the transcripto-
gram in the middle third of the panel (with horizontal
Table 2 KEGG pathways and GO terms identified as differentially expressed by GSEA analysis
Size ES NES Normal P value FDR FWER P value
NC-ADPKD/NK, upregulated in NK
KEGG_drug_metabolism_cytochrome_p450 42 0.8 2.17 0 0 0
KEGG_metabolism_of xenobiotics_by_cytochrome p450 42 0.7 2.06 0 0 0.001
KEGG_histidine_metabolism 22 0.8 1.94 0 0.006 0.019
KEGG_glutathione_metabolism 38 0.7 1.86 0 0.013 0.049
KEGG_fatty_acid_metabolism 32 0.6 1.73 0.004 0.048 0.209
C-ADPKD/NK, upregulated in C-ADPKD
KEGG_chemokine_signaling_pathway 144 −1 −1.73 0 0.01 0.011
KEGG_axon_guidance 99 −1 −1.68 0 0.03 0.066
KEGG_leukocyte_transendothelial_migration 86 −1 −1.66 0.001 0.028 0.092
GOBP_cell_cell_adhesion 48 0.8 1.8 0 0.001 0.001
NC-ADPKD/C-ADPKD, upregulated in C-ADPKD
KEGG_leukocyte_transendothelial_migration 86 −1 −1.82 0 0 0
KEGG_chemokine_signaling_pathway 144 −1 −1.74 0 0.024 0.05
KEGG_tight_junction 101 −1 −1.73 0 0.02 0.063
KEGG_axon_guidance 99 −1 −1.73 0 0.016 0.066
GOBP_cell_cell_adhesion 48 0.8 1.8 0 0.007 0.008
Listing of KEGG pathways and GO terms with FDR < 5%. GSEA expresses all differences as upregulation to minimize class bias due to the intrinsic asymmetry of
the method
Fig. 3 Term enrichment map showing the correspondence between the ordered gene list and major biological terms and pathways. The x-axis
indicates the relative position in the ordered list of 9684 genes. The colored profiles give the density distributions within the list of specific GO
terms or KEGG pathways. A term enrichment value of 1 on the y-axis indicates that all genes in an interval of radius r = 30 participate in a given
GO term or KEGG pathway. Peaks mark regions enriched with genes related to the term or pathway indicated in the legend. The legend orders
the terms/pathways from left to right
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lines indicating p = 0.05 and 0.01), and plots of peaks
from the term enrichment density profile that corres-
pond to significant peaks in the transcriptogram in the
lower third of the panel. We calculated FDR values for
all comparisons (Table 3).
Using transcriptogram analysis, we first compared the
expression profiles of NK and NC-ADPKD samples
(Fig. 4). Across most of the ordered list, the standard
errors of the expression levels of genes for the NK and
NC-ADPKD cells overlap, showing that gene expression
levels of these genes in NC-ADPKD cells do not differ
significantly from normal. However, gene positions
between 0.22 and 0.26 and the intervals centered at po-
sitions 0.46 and 0.88 show significant differences
(P < 0.01 and FDR < 0.12). The term enrichment profile
shows that these significant peaks correspond to ‘cell
cycle,’ ‘locomotory behavior,’ ‘NOD (nucleotide-binding
oligomerization domain)-like receptor signaling,’ and
‘Potassium ion transport’ (Fig. 4). When we analyzed
the gene lists from each interval of differential expression
to identify additional pathways and terms, we found add-
itional differentially expressed gene sets related to ‘cell
cycle,’ ‘nucleotide metabolism,’ ‘genetic information pro-
cessing,’ ‘immune response,’ and ‘ion transport’ (Figs. 7, 8,
9, 11, 13). We examined individual gene expression pro-
files from two of these pathways, ‘NOD-like receptors’ and
‘potassium ion transport’. Genes differentially expressed at
significant levels (Figs. 12a, 11b) may be potential targets
for drug interventions to prevent or ameliorate very early
stages of cyst growth.
Transcriptogram analysis comparing the NK and C-
ADPKD samples (Fig. 5) detected additional regions of
significant difference (where P < 0.01 and FDR < 0.12).
The term enrichment profile shows that these significant
peaks correspond to alterations in ‘RNA processing,’ ‘cell
cycle,’ ‘nucleic acid processing and metabolism,’ ‘G-pro-
tein signaling,’ ‘immune response,’ and ‘cell fate’ related
pathways including ‘Calcium signaling’ and ‘JAK-STAT’
pathways, ‘wound healing,’ ‘extracellular matrix,’ ‘cell
adhesion and tight junctions,’ as well as energy-related
gene sets for ‘oxidative phosphorylation’ and the ‘TCA
(tricarboxylic acid cycle) cycle,’ and the ‘drug-metabolism
related cytochrome P450’. Analysis of the gene lists
from each interval of differential expression identified
additional related pathways and terms (Figs. 7, 8, 9, 10,
11, 12, 13, and 14). Overall, C-ADPKD cells have lower-
than-normal metabolic rates and lower-than-normal
expression levels of genes associated with ‘cell prolifera-
tion,’ ‘RNA (ribonucleic acid) metabolism,’ and ‘sugar,
lipid and energy metabolism’. Additionally, their inter-
action with the extracellular environment is strongly
altered as indicated by enhanced expression of ‘cell
adhesion,’ ‘tight junction,’ and ‘cell surface signaling’
pathways. Thus, C-ADPKD cells have abnormal interac-
tions with their extracellular environment.
Although cell cycle regulation is abnormal in both NC-
ADPKD and C-ADPKD cells, expression of cell-cycle-re-
lated genes is higher-than-normal in NC-ADPKD sam-
ples and lower-than-normal in C-ADPKD samples.
Additional pathways and terms identified from gene lists
of the cell cycle or RNA metabolism-associated intervals
(Figs. 7, 8, and 9) present a consistent pattern: expression
in the NC-ADPKD sample is higher than normal and ex-
pression in C-ADPKD sample is lower than normal. This
pattern of cell-cycle regulation disruption deserves future
investigation since the genes included in this gene set ini-
tiate and regulate cell cycle progression making it difficult
to predict the net effect on cell proliferation.
We then used transcriptogram analysis to compare NC-
ADPKD and C-ADPKD samples (Fig. 6). Because NC-
ADPKD and NK samples have very similar expression
profiles (Fig. 4), the transcriptogram comparison of NC-
ADPKD to C-ADPKD samples is similar to the transcrip-
togram comparison of NK to C-ADPKD samples. How-
ever, because NC-ADPKD and C-ADPKD samples derive
from cystic and non-cystic tissues from the same kidney,
standard errors and consequently, P values for this com-
parison are very small. However, the location of the most
significant peaks and valleys are nearly identical in both
comparisons. Many of the pathways and terms differen-
tially expressed between NC-ADPKD and C-ADPKD
samples (Figs. 6, 7, 8, 9, and 10) are also differentially
expressed between NK and C-ADPKD samples.
Gene sets associated with significantly altered
transcriptogram intervals
Transcriptogram values indicating significant differential
expression do not directly refer to pathways or terms,
but rather to intervals of the ordered list enriched with
genes for specific pathways and terms. Therefore, subse-
quent to transcriptogram analysis (Figs. 3, 4, and 5), we
fed the gene lists from each identified interval of differen-
tial expression into the publicly available David functional
Table 3 False discovery rates
False discovery rates
P value NC-ADPKD/NK C-ADPKD/NK C-ADPKD/NC-ADPKD
0.1 0.131545 0.140392 0.0970966
0.05 0.137393 0.120033 0.0869387
0.01 0.100738 0.112763 0.0809876
0.005 0.100182 0.1156 0.0804989
0.001 0 0.106 0.0800862
0.0005 0 0 0.0800589
0.0001 0 0 0.08
5.00E−05 0 0 0.08
False discovery rates (FDR) for relative transcriptograms obtained using 500
sample-label permutations
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Fig. 4 Relative transcriptogram for NC-ADPKD/NK. The x-axis indicates the relative positon in the ordered list of 9684 genes. Upper panel the
relative transcriptograms are presented as means ± s.e.m. with NC-ADPKD (blue line ± cyan region) and NK (black line ± gray region) given relative
to NK. Center panel (shaded gray): P value from a two-tailed Weyl’s t test is plotted for each point of the transcriptograms. Horizontal lines mark
P = 0.05 and P = 0.01. Location in the ordered list of Pkd1 and Pkd2, the causative genes for ADPKD, is shown. Lower panel Term enrichment for
transcriptogram regions with significantly changed expression. A term enrichment value of 1 on the y-axis indicates that all genes in an interval
of radius r = 30 participate in a given GO term or KEGG pathway. As an example of how to read the relative transcriptogram figures, NC-ADPKD
cells have higher-than-normal gene expression in the region of the peak labeled ‘cell cycle’ in the upper panel with a significance of P < 0.01
(middle panel). This region is enriched with genes associated with ‘cell cycle’ KEGG terms and GO pathways (marked with a bar and identified
by referring to the lower panel, which shows term enrichment)
Fig. 5 Relative transcriptogram for C-ADPKD/NK. The x-axis indicates the relative position in the ordered list of 9684 genes. Upper panel We present
the relative transcriptograms as means ± s.e.m. with C-ADPKD (red line ± pink region) and NK (black line± gray region) given relative to NK. Center panel
(shaded gray): P value from a two-tailed Weyl’s t test for each point of the transcriptogram. Horizontal lines mark P = 0.05 and P = 0.01. We label
the location in the ordered list of Pkd1 and Pkd2, the causative genes for ADPKD. Lower panel Term enrichment for transcriptogram regions with
gene expression significantly different from normal. A term enrichment value of 1 on the y-axis indicates that all genes in an interval of radius
r = 30 participate in a given GO term or KEGG pathway
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tools [36, 37] to identify additional KEGG pathways (path-
ways) and GO terms (terms) associated with those inter-
vals. We then had to consider the differential expression
of particular pathways and terms independently. For each
of these pathways and terms, we calculated average ex-
pression levels and determined significance using Welch’s
two tail t test (Figs. 7, 8, 9, 10, 11, 12, 13, and 14). Finally,
we categorized these pathways and terms according to the
KEGG pathway map and GO term hierarchies, grouping
together functionally overlapping pathways and terms
from KEGG and GO.
Differentially regulated KEGG pathways and GO terms
identified from gene set analyses
NC-ADPKD samples had higher-than-normal and C-
ADPKD samples lower-than-normal expression of path-
ways and terms associated with ‘cell proliferation’ (Fig. 7).
Both NC-ADPKD and C-ADPKD samples had higher-
than-normal expression of ‘cell-death-related’ terms.
These expanded results agree with the terms identified
using the transcriptogram ordered gene list (Figs. 3, 4,
and 5). Consistent with the changes seen in ‘cell growth,’
‘genetic information processing,’ (Fig. 8) and ‘amino acid
metabolism’ (Fig. 9), pathways and terms are higher than
normal in NC-ADPKD samples and lower than normal
in C-ADPKD samples. The one exception to this pat-
tern, the KEGG ‘ribosome pathway,’ is higher than nor-
mal in both NC-ADPKD and C-ADPKD samples. These
results suggest that treatments that target cell prolifera-
tion are likely to be effective in patients in which cysts
have not yet begun to form and ineffective in patients
with significant cyst formation. Pathways and terms with
abnormal expression in NC-ADPKD samples pique our
interest because changes that occur before cysts form
have the greatest potential as targets for amelioration of
cyst formation.
Conventional gene chip analysis has not identified
pathways that explained the cell de-differentiation ob-
served in cystic cells [38, 39]. Our analysis has revealed
a group of signal transduction pathways and terms that
are abnormal in ADPKD (Fig. 10). Both NC-ADPKD
and C-ADPKD samples have higher-than-normal expres-
sion of most signal-transduction pathways. Elevated ‘cyclic
nucleotide related’ pathways are not surprising, given cyc-
lic AMP’s role in promoting cyst expansion [40, 41]. Both
NC-ADPKD and C-ADPKD samples have higher-than-
normal expression of Wnt and Notch pathways, which
enhance proliferation, increase resistance to apoptosis
Fig. 6 Relative transcriptogram for C-ADPKD/NC-ADPKD. The x-axis indicates the relative positon in the ordered list of 9684 genes. Upper panel
The relative transcriptograms are presented as means ± s.e.m. with C-ADPKD (red line ± pink region) and NC-ADPKD (blue line ± cyan region)
relative to NC-ADPKD. Center panel (shaded gray): P value from a two tailed Weyl’s t test for each point of the transcriptogram. Horizontal lines
mark P = 0.05 and P = 0.01. We label the location in the ordered list of Pkd1 and Pkd2, the causative genes for ADPKD. Lower panel: Term
enrichment for transcriptogram regions with gene expression significantly different from normal. A term enrichment value of 1 on the y-axis
indicates that all genes in an interval of radius r = 30 participate in a given GO term or KEGG pathway. P values between C-ADPKD and NC-
ADPKD cells are smaller than between either C-ADPKD or NC-ADPKD and NK cells (see Figs. 4 and 5) because C-ADPKD and NC-ADPKD cells
were derived from the same individual, allowing us to discriminate additional differentially expressed regions
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Fig. 8 Genetic information processing is altered in ADPKD. NC-ADPKD cells have higher-than-normal expression and C-ADPKD cells have
lower-than-normal expression of genes from all ‘Genetic information processing’ gene sets except the KEGG ribosome gene set. We present
data as mean ± s.e.m., **P < 0.01, *P < 0.05 (black asterisk is in comparison to NK, gray asterisk is in comparison to NC-ADPKD). Genetic Information
Processing Gene Sets: (1) KEGG_DNA_REPLICATION, (2) KEGG_BASE_EXCISION_REPAIR, (3) KEGG_NUCLEOTIDE_EXCISION_REPAIR, (4) KEGG_
MISMATCH_REPAIR, (5) KEGG_HOMOLOGOUS_RECOMBINATION, (6) DNA_REPLICATION, (7) DNA_REPAIR, (8) KEGG_RNA_POLYMERASE, (9)
KEGG_BASAL_TRANSCRIPTION_FACTORS, (10) KEGG_SPLICEOSOME, (11) TRANSCRIPTION, (12) REGULATION_OF_TRANSCRIPTION, (13) TRANSCRIPTION_
DNA_DEPENDENT, (14) REGULATION_OF_TRANSCRIPTION_DNA_DEPENDENT, (15) TRANSCRIPTION_FROM_RNA_POLYMERASE_II_PROMOTER,
(16) KEGG_RIBOSOME, (17) RIBONUCLEOPROTEIN_COMPLEX_BIOGENESIS_AND_ASSEMBLY, (18) PROTEIN_RNA_COMPLEX_ASSEMBLY, (19)
MRNA_PROCESSING_GO_0006397, (20) RNA_SPLICING_VIA_TRANSESTERIFICATION_REACTIONS
Fig. 7 Both cell growth and cell death are altered in ADPKD. NC-ADPKD cells have higher-than-normal expression and C-ADPKD cells have
lower-than-normal expression of genes from ‘cell growth’ gene sets. Both NC-ADPKD and C-ADPKD cells have higher-than-normal expression
of genes from ‘cell death’ gene sets. We present data as mean ± s.e.m., **P < 0.01, *P < 0.05 (black asterisk is in comparison to NK, gray asterisk is in
comparison to NC-ADPKD). Cell Growth Gene Sets: (1) KEGG_CELL_CYCLE, (2) CELL_CYCLE, (3) CELL_CYCLE_CHECKPOINT, (4) CELL_CYCLE_PROCESS,
(5) CELL_CYCLE_PHASE, (6) MITOTIC_M_PHASE, (7) MITOTIC_CELL_CYCLE, (8) M_PHASE, (9) MITOSIS. Cell Death Gene Sets: (10) KEGG_APOPTOSIS,
(11) APOPTOTIC_PROCESS, (12) PROGRAMMED_CELL_DEATH
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and inhibit differentiation of epithelial cells [42]. The
excess expression is greater in NC-ADPKD than in C-
ADPKD samples, again suggesting possible targets for
prevention of cyst initiation.
Chronic non-resolving inflammation accompanies cyst
accumulation in ADPKD [43]. Our analysis identified
multiple ‘immune response’ pathways with abnormal ex-
pression (Fig. 11). All but one of the identified ‘immune
response’ pathways had higher-than-normal expression in
NC-ADPKD samples and further increased expression in
C-ADPKD samples, consistent with increased inflamma-
tory response as cysts accumulate. Notably, the morpho-
logically normal NC-ADPKD-derived cells already showed
higher-than-normal expression of ‘immune response’
pathways, suggesting that components of the immune re-
sponse could provide targets to ameliorate the progression
of ADPKD. An exception to this pattern was the lower-
than-normal expression of the KEGG ‘complement and
coagulation’ pathway in C-ADPKD samples.
‘Response-to-stimulus’ gene groups are overexpressed
in kidney carcinoma [44]. Our analysis identifies multiple
‘response-to-stimulus’ terms with increased expression in
ADPKD (Fig. 12), suggesting mechanistic similarities
between PKD and kidney carcinoma [45]. All but one of
the identified ‘response-to-stimulus’ terms had higher-
than-normal expression in NC-ADPKD samples and fur-
ther increased expression in C-ADPKD samples. In C-
ADPKD samples, expression of ‘response-to-endogen-
ous-stimulus’ genes was lower than normal and also
lower than in NC-ADPKD samples.
Establishment and maintenance of epithelial cell polar-
ity are prerequisites for normal function of all epithelial
organs. Epithelia depend on cell adhesion molecules to
adapt and respond to mechanical forces and cell density,
while tight junctions control diffusion across the epithe-
lial layer. Transcriptogram analysis shows that both NC-
ADPKD and C-ADPKD cells have higher-than-normal
expression of genes in the ‘cell-adhesion-molecule’ and
‘tight-junction’ KEGG pathways (Fig. 12). Nephron seg-
ments differentially express multiple tight-junction pro-
teins which may determine segment specific paracellular
permeability [46]. ADPKD cyst epithelia express claudin-7
in an abnormal distribution on the apical and basolateral
membrane [47]. Decreased presence of strong E-cadherin
Fig. 9 Nucleotide metabolism is abnormal in ADPKD. NC-ADPKD cells have higher-than-normal expression and C-ADPKD cells have lower-than-normal
expression of genes from all ‘Nucleotide Metabolism’ gene sets. We present data as mean ± s.e.m., **P< 0.01, *P < 0.05 (black asterisk is in comparison to
NK, gray asterisk is in comparison to NC-ADPKD). Nucleotide Metabolism Gene Sets: (1) KEGG_PURINE_METABOLISM, (2) KEGG_PYRIMIDINE_METABOLISM,
(3) RNA_SPLICING, (4) MRNA_METABOLIC_PROCESS, (5) NEGATIVE_REGULATION_OF_TRANSCRIPTION, (6) REGULATION OF NUCLEOBASE_NUCLEOSIDE_
NUCLEOTIDE_AND_NUCLEIC_ACID_METABOLIC_PROCESS, (7) RNA_BIOSYNTHETIC_PROCESS, (8) NEGATIVE_REGULATION_OF NUCLEOBASE_
NUCLEOSIDE_NUCLEOTIDE_AND_NUCLEIC_ACID_METABOLIC_PROCESS, (9) CHROMOSOME_ORGANIZATION_AND_BIOGENESIS,
(10) DNA_METABOLIC_PROCESS
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Fig. 10 ADPKD upregulates signal transduction. NC-ADPKD and C-ADPKD cells have higher-than-normal expression of genes from all signal
transduction gene sets. Expression levels in NC-ADPKD cells are intermediate between those of NK and C-ADPKD cells, exception that expression
levels of Wnt and Notch signaling pathways are higher in NC-ADPKD cells. These pathways are normally active primarily during embryonic
development. We present data as mean ± s.e.m., **P < 0.01, *P < 0.05 (black asterisk is in comparison to NK, gray asterisk is in comparison to
NC-ADPKD). Signal Transduction Gene Sets: (1) G_PROT._COUPLED_RECEPTOR_PROTEIN_SIGNALING, (2) G_PROT._SIGNALING_COUPLED_TO_
CYCLIC_NUCLEOTIDE_2ND_MESS, (3) G_PROT._SIGNALING_COUPLED_TO_CAMP_NUCLEOTIDE_2ND_MESS, (4) G_PROT._SIGNALING_ADENYLATE_
CYCLASE_ACTIVATING, (5) CAMP_MEDIATED_SIGNALING, (6) CELL_CELL_SIGNALING, (7) SYNAPTIC_TRANSMISSION, (8) CYCLIC_NUCLEOTIDE_
MEDIATED_SIGNALING, (9) KEGG_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION, (10) KEGG_NEUROACTIVE_LIGAND_RECEPTOR_INTERACTION,
(11) KEGG_ERBB_SIGNALING_PATHWAY, (12) KEGG_WNT_SIGNALING_PATHWAY, (13) KEGG_NOTCH_SIGNALING_PATHWAY, (14) KEGG_CALCIUM_
SIGNALING_PATHWAY, (15) KEGG_JAK_STAT_SIGNALING_PATHWAY, (16) KEGG_ABC_TRANSPORTERS
Fig. 11 Immune response is abnormal in ADPKD. NC-ADPKD and C-ADPKD cells both express higher-than-normal levels of genes from ‘immune
response’ gene sets, exception that C-ADPKD cells have lower-than-normal expression of the KEGG ‘Complement and Coagulation cascade’ gene
set (12). We present data as mean ± s.e.m., **P < 0.01, *P < 0.05 (black asterisk is in comparison to NK, gray asterisk is in comparison to NC-ADPKD).
Immune Response Gene Sets: (1) INFLAMMATORY_RESPONSE, (2) IMMUNE_RESPONSE, (3) HUMORAL_IMMUNE_RESPONSE, (4) CELL_ACTIVATION,
(5) IMMUNE_SYSTEM_PROCESS, (6) LEUKOCYTE_ACTIVATION, (7) LYMPHOCYTE_ACTIVATION, (8) KEGG_CHEMOKINE_SIGNALING_PATHWAY,
(9) KEGG_NOD_LIKE_RECEPTOR_SIGNALING_PATHWAY, (10) KEGG_T_CELL_RECEPTOR_SIGNALING_PATHWAY, (11) KEGG_LEUKOCYTE_
TRANSENDOTHELIAL_MIGRATION, (12) KEGG_COMPLEMENT_AND_COAGULATION_CASCADES, (13) KEGG_CYTOSOLIC_DNA_SENSING_
PATHWAY, (14) KEGG_HEMATOPOIETIC_CELL_LINEAGE, (15) KEGG_FC_GAMMA_R_MEDIATED_PHAGOCYTOSIS
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adhesion molecules on the tubule cell surface, accom-
panied by upregulation of weaker cell-cell adhesion by
N-cadherin and cadherin-8 are also known components
of ADPKD [48, 49]. This lower-than-normal cell-cell
adhesion accompanies higher-than-normal expression
of cell motility terms, both hallmarks of epithelial to
mesenchymal transition and cellular de-differentiation.
Defects in urine concentration are a well-established
component of ADPKD [50]. NC-ADPKD samples had
slightly higher-than-normal and C-ADPKD samples had
significantly lower-than-normal expression of ‘vasopres-
sin-regulated water reabsorption’ [51] and ‘proximal tubule
bicarbonate reclamation’ [52] pathways (Fig. 13).
ADPKD causes widespread disruptions of metabolism
(Fig. 14). Of the metabolic pathways and terms identi-
fied, ‘cofactor and vitamin metabolism’ and ’amino acid
and energy metabolism’ were all decreased in C-
ADPKD samples. ‘Carbohydrate, drug, lipid and glycan
metabolism’ pathways were lower than normal in C-
ADPKD samples with the exception of ‘fructose and
mannose,’ ‘galactose,’ and ‘amino sugar and nucleotide
sugar metabolism’. ‘Drug metabolism cytochrome P450’
pathway expression levels were lower than normal in
both NC-ADPKD and C-ADPKD samples. ‘Lipid metab-
olism’ pathway expression was significantly abnormal,
but with mixed expression effects. ‘Glycan metabolism’
pathway expression was slightly higher than normal in
NC-ADPKD samples and lower than normal in C-
ADPKD samples.
The differential expression of pathways and terms
(Figs. 7, 8, 9, 10, 11, 12, 13, and 14) in the gene sets as-
sociated with significantly altered transcriptogram in-
tervals (Figs. 4, 5, and 6) provides strong evidence that:
1) ‘Proliferation,’ ‘genetic information processing,’ and
‘nucleotide metabolism’ pathways and terms are
higher-than-normal in NC-ADPKD and lower-than-
normal in C-ADPKD, while ‘apoptosis’ is higher-
than-normal in both NC-ADPKD and C-ADPKD.
2) ‘Immune response’ pathways and terms overall are
upregulated in both NC-ADPKD and C-ADPKD.
3) Changes in ‘signal transduction’ and ‘cellular process’
pathways are consistent with de-differentiation of
epithelial cells in ADPKD.
4) ‘Metabolism’ pathways and terms overall are
downregulated in ADPKD.
Fig. 12 Response to stimulus and cellular processes are abnormal in ADPKD. Both NC-ADPKD and C-ADPKD cells have higher-than-normal expression
of genes in the ‘response to stimulus’ gene sets (1–8), except that C-ADPKD cells have lower-than-normal expression of genes in the ‘response to
endogenous stimulus’ gene set. C-ADPKD cells have higher-than-normal expression of genes in the ‘cellular processes’ gene sets (9–11). Data are
represented as mean ± s.e.m., **P < 0.01, *P < 0.05 (black asterisk is in comparison to NK, gray asterisk is in comparison to NC-ADPKD). Response to
Stimulus Gene Sets: (1) RESPONSE_TO_ENDOGENOUS_STIMULUS, (2) RESPONSE_TO_EXTERNAL_STIMULUS, (3) REGULATION_OF_RESPONSE_TO_
STIMULUS, (4) DEFENSE_RESPONSE, (5) CELLULAR_DEFENSE_RESPONSE, (6) RESPONSE_TO_WOUNDING, (7) COAGULATION, (8) BLOOD_COAGULATION.
Cellular Processes Gene Sets: (9) KEGG_TIGHT_JUNCTION, (10) KEGG_GAP_JUNCTION, (11) LOCOMOTORY_BEHAVIOR
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We therefore posit that genes from the pathways and
terms that are uniquely altered in NC-ADPKD samples
(e.g., before cysts have formed) have the greatest poten-
tial as drug targets for ameliorating cyst formation.
Finding individual candidate genes
We next examine the expression levels of the individual
genes (Fig. 15) in selected pathways and terms which
transcriptogram analysis identifies as differentially
expressed at a significant level (Figs. 7, 8, 9, 10, 11, 12,
13 and 14). Selection of pathways and terms for further
examination was based on significance level and rele-
vance to the existing literature. These genes likely play
key roles in development of ADPKD and are thus po-
tential targets for drug therapies to prevent or delay
ADPKD. Figure 15 shows the levels of expression of in-
dividual genes from three pathways and terms, ‘Nod-
like receptor signaling’ a term from ‘immune response,’
‘potassium ion transport’ a term from ‘ion homeostasis,’
and ‘oxidative phosphorylation’ a term from ‘energy
metabolism’. We then confirmed expression levels of
individual genes in these pathways and terms using
qRT-PCR (Additional file 3).
The intracellular NOD-like receptor (NLR) family
plays a central role in regulation of the innate immune
response. The NLRs NOD1 and NOD2 sense bacterial
peptidoglycan fragments and respond by stimulating the
activation of NF-κB (nuclear factor kappa beta) and
MAPK, cytokine production, and apoptosis. The NLRs
NALP1 (NLR-pyrin containing), NALP3 and Ipaf acti-
vate caspase-1 through inflammasomes, which generate
pro-inflammatory cytokines. NOD-like receptor signaling
contributes to multiple renal diseases with inflammatory
components, including ureteric obstruction, ischemia
reperfusion injury, glomerulonephritis, sepsis, hypoxia,
glycerol-induced renal failure, and crystal nephropathy
[53–55]. However, neither the Volcano plots nor GSEA
analysis found abnormal activity of NOD-like receptor
signaling in ADPKD cells. We examined expression of the
20 individual genes involved in the KEGG ‘NOD-like
receptor signaling’ pathway (Fig. 15a) that were present in
our microarrays. In NC-ADPKD cells, all but one of the
20 NOD-like receptor signaling genes had higher-than-
normal expression (Fig. 15a), suggesting that that reducing
NOD-like receptor signaling early in ADPKD might
ameliorate the progression of the disease. C-ADPKD cells
Fig. 13 Ion homeostasis and transport are abnormal in ADPKD. NC-ADPKD cells have higher-than-normal and C-ADPKD cells have much higher-
than-normal expression of genes in ‘ion homeostasis’ gene sets (1–8). NC-ADPKD cells have higher-than-normal expression of genes in ‘transport’
gene sets (9–11). We represent data as mean ± s.e.m, **P < 0.01, *P < 0.05 (black asterisk is in comparison to NK, gray asterisk is in comparison to
NC-ADPKD). Ion Homeostasis Gene Sets: (1) ION_HOMEOSTASIS, (2) CELLULAR_CATION_HOMEOSTASIS, (3) ION_TRANSPORT, (4) METAL_ION_TRANSPORT,
(5) CATION_TRANSPORT, (6) POTASSIUM_ION_TRANSPORT, (7) CALCIUM_ION_TRANSPORT, (8) MONOVALENT_INORGANIC_CATION_TRANSPORT.
Transport Gene Sets: (9) KEGG_VASOPRESSIN_REGULATED_WATER_REABSORPTION, (10) KEGG_PROXIMAL_TUBULE_BICARBONATE_RECLAMATION,
(11) REGULATION_OF_BODY_FLUID_LEVELS
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Fig. 14 (See legend on next page.)
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also had higher-than-normal expression levels of several
of these genes, including tumor necrosis factor (TNF).
TNF blockers are an approved treatment for debilitating
chronic inflammatory diseases, in particular rheumatoid
arthritis (RA) so tumor necrosis factor (TNF) blockers
specifically and NOD-like receptor signaling blockers in
general may be worth testing for treatment of ADPKD.
Even if they do not slow cyst progression, they may reduce
the chronic pain associated with inflammatory diseases
like ADPKD.
The kidney is the primary regulator of total body
potassium content. Maintenance of proper levels and
distribution of potassium across the cell membrane is
critical for normal cell function [56]. Further, potassium
channels are critical for cAMP-dependent chloride se-
cretion and cyst growth in ADPKD [57]. We examined
expression of the 11 individual genes in our microarrays
with the GO ‘potassium ion transport’ label (Fig. 15c).
Our analysis revealed changes of expression of ‘potassium
ion transport’ as a category and of individual genes within
that category, which neither Volcano plotting or GSEA
analysis was able to identify.
Pkd1−/− cells and kidneys from cystic mice preferen-
tially rely on aerobic glycolysis for their energy demands,
a metabolic switch similar to the Warburg effect in cancer
cells [58]. Our analysis revealed changes in pathways and
terms related to ‘energy metabolism’ that conventional
volcano and GSEA analysis missed. We examined expres-
sion of the 20 individual genes in the KEGG ‘oxidative
phosphorylation’ pathway (Fig. 15b) that were present in
our microarrays. Expression of all oxidative phosphoryl-
ation related genes was significantly lower than normal in
both C-ADPKD and NC-ADPKD samples, with greater
reduction in C-ADPKD samples. Volcano plotting also
identified phosphoenolpyruvate carboxy-kinase 1 (Pck1)
as significantly differentially expressed (Fig. 1); the Pck1
enzyme is a main control point for the regulation of glu-
coneogenesis. Pck1 expression in NC-ADPKD samples
is 5.58 times higher than normal (p = 1.54 × 10− 8) and is
0.58 times lower than normal (not significant) in C-
ADPKD samples.
Discussion
In this communication, we compare gene expression
profiles between a paired age and sex-matched pair of
telomerase immortalized human cell lines (NK and
PKD). A second grouped pair of immortalized human
cell lines (NC-ADPKD and C-ADPKD) was derived from
renal cysts and normal appearing nephrons from the
same human male polycystic kidney. The choice to use
immortalized cell lines as the source material to isolate
RNA was based on our prior unsuccessful attempts to
obtain good-quality RNA from polycystic kidneys. Due
to their large size and the need to cross clamp the kidneys
at the renal pedicle, we obtained poor-quality RNA iso-
lated from the nephrectomy specimen likely because of
prolonged warm ischemia time. While the use of cell lines
allowed us to eliminate the issue of RNA degradation, it
also brings forward the question as to how generalizable is
the data presented in this communication. In our review,
the group that solved the problem of obtaining high-
quality RNA from polycystic kidney surgical specimens
was Song et al. [17]. Our preliminary analysis of that data
set using the transcriptogram approach shows a close
concordance between our data and Song’s data. This
comparison will be the subject of a future communication.
(See figure on previous page.)
Fig. 14 ADPKD broadly perturbs metabolism. a Cofactor and vitamin, amino acid, and energy metabolism and b carbohydrate, drug, lipid, and
glycan metabolism. C-ADPKD cells have lower-than-normal expression of genes in ‘cofactor and vitamin’ gene sets (A1-2) compared to both NK
and NC-ADPKD cells. Both NC-ADPKD and C-ADPKD cells have lower-than-normal expression of genes in ‘amino acid’ gene sets (A3-11). C-ADPKD
cells have lower-than-normal expression of genes in ‘energy metabolism’ gene sets (A12-14). C-ADPKD cells have lower-than-normal expression of
genes in all ‘carbohydrate metabolism’ gene sets (B1-9) except for the KEGG ‘histidine metabolism’ gene set. C-ADPKD cells have lower-than-normal
expression of genes in the ‘drug metabolism’ gene set (B10). C-ADPKD cells have lower-than-normal expression of genes in all ‘lipid metabolism’ (B11-18)
gene sets except for the KEGG ‘arachidonic acid metabolism’ gene set (B13). C-ADPKD cells have lower-than-normal expression of genes in ‘glycan
metabolism’ gene sets (B19-20). We present data as mean ± s.e.m., **P< 0.01, *P< 0.05 (black asterisk is in comparison to NK, gray asterisk is in comparison
to NC-ADPKD). a Cofactor and vitamin, amino acid, and energy metabolism gene sets. Cofactor and Vitamin Gene Sets: (1) KEGG_RETINOL_METABOLISM,
(2) KEGG_PORPHYRIN_AND_CHLOROPHYLL_METABOLISM. Amino Acid Metabolism Gene Sets: (3) KEGG_ALANINE_ASPARTATE_AND_GLUTAMATE_
METABOLISM, (4) KEGG_GLYCINE_SERINE_AND_THREONINE_METABOLISM, (5) KEGG_VALINE_LEUCINE_AND_ISOLEUCINE_DEGRADATION, (6) KEGG_
ARGININE_AND_PROLINE_METABOLISM, (7) KEGG_HISTIDINE_METABOLISM, (8) KEGG_TRYPTOPHAN_METABOLISM, (9) KEGG_BETA_ALANINE_
METABOLISM, (10) KEGG_SELENOAMINO_ACID_METABOLISM, (11) KEGG_GLUTATHIONE_METABOLISM. Energy Metabolism Gene Sets: (12) KEGG_
OXIDATIVE_PHOSPHORYLATION, (13) MITOCHONDRIAL_TRANSPORT, (14) MITOCHONDRION_ORGANIZATION_AND_BIOGENESIS. b Carbohydrate,
drug, lipid and glycan metabolism gene sets. Carbohydrate Metabolism Gene Sets: (1) KEGG_GLYOXYLATE_AND_DICARBOXYLATE_METABOLISM,
(2) KEGG_PROPANOATE_METABOLISM, (3) KEGG_BUTANOATE_METABOLISM (4) KEGG_GLYCOLYSIS_GLUCONEOGENESIS, (5) KEGG_CITRATE_CYCLE_
TCA_CYCLE, (6) KEGG_PYRUVATE_METABOLISM, (7) KEGG_FRUCTOSE_AND_MANNOSE_METABOLISM, (8) KEGG_GALACTOSE_METABOLISM, (9) KEGG_
AMINO_SUGAR_AND_NUCLEOTIDE_SUGAR_METABOLISM. Drug Metabolism Gene Sets; (10) KEGG_DRUG_METABOLISM_CYTOCHROME_P450.
Lipid Metabolism Gene Sets: (11) KEGG_GLYCEROLIPID_METABOLISM, (12) KEGG_GLYCEROPHOSPHOLIPID_METABOLISM, (13) KEGG_ARACHIDONIC_
ACID_METABOLISM, (14) KEGG_LINOLEIC_ACID_METABOLISM, (15) KEGG_SPHINGOLIPID_METABOLISM, (16) KEGG_FATTY_ACID_METABOLISM,
(17) KEGG_STEROID_HORMONE_BIOSYNTHESIS, (18) PHOSPHOLIPID_BIOSYNTHETIC_PROCESS. Glycan Metabolism Gene Sets: (19) KEGG_N_GLYCAN_
BIOSYNTHESIS, (20) KEGG_GLYCOSYLPHOSPHATIDYLINOSITOL_GPI_ANCHOR_BIOSYNTHESIS
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Other evaluations of gene expression data have relied on
murine cell lines or RNA isolated from newly formed
cysts from conditional knockout models, and results from
these studies identify similar themes for aberrant signaling
such as immune defense, cell structure and motility, cellu-
lar proliferation, apoptosis, and metabolic control [59–62].
These are GSEA findings that are also observed in our
study suggesting that a subset of findings observed in our
cell lines are generalizable.
Current analyses of genome-wide gene expression
measurements (microarrays or RNASeq, for example)
such as single gene Volcano plots (Fig. 1) and GSEA
gene set analysis (Tables 1 and 2) have failed to identify
patterns of gene expression that define specific diseases
or reveal the entirety of their molecular mechanisms of
pathogenesis. Our ADPKD transcriptogram analysis
(Figs. 4, 5, and 6) identified more significantly altered
KEGG pathways and GO terms than either Volcano
plots (Fig. 2) or GSEA analysis (Tables 1 and 2). Import-
antly, transcriptogram analysis identifies additional path-
ways and terms which are consistent with what we know
about signaling, functional, and morphological changes
that occur in ADPKD, clarifying the mechanisms by which
PKD mutations drive cyst formation.
Comparing global gene expression profiles between NK,
ADPKD, NC-ADPKD, and C-ADPKD shows that the NC-
ADPKD gene profile is most similar to the NK line ex-
pression profile. The NK cell line profile is markedly dif-
ferent from both the C-ADPKD and end-stage ADPKD
cell line gene expression profiles (Additional file 5: Figure
S5). NC-ADPKD, C-ADPKD, and ADPKD cell lines all
have truncation mutations in one allele of the PC-1 gene.
However, when we sequenced the PC-1 genomic clones,
we found no evidence for second somatic mutations in
the PC-1 gene [25]. Additionally, there were no differences
in total polycystin-1 and 2 protein expression in the
ADPKD cell line [25]. The sole distinguishing feature
between the NK and ADPKD cell lines was the absence of
polycystin-1 in the cilia of the ADPKD cells [63]. Our
transcriptogram analysis suggests that some other genetic
event, i.e., a second hit, causes the dramatic shift in gene
expression which transforms non-cystic ADPDK cells into
cystic ADPKD cells [64]. The transition in expression pro-
files may have been determined during the early steps of
cyst emergence that set the subsequent gene expression
profile to reflect a fundamentally altered differentiation
profile [17] [65]. Alternatively, a second somatic mutation
that launched cyst emergence occurred in some other
cystogenic gene site where we have incomplete informa-
tion at present [66, 67]. Notably, in a murine conditional
PKD1 knockout, cyst formation is most robust with PKD1
inactivation up to post-natal day 14 [68]. In other knock
out models, cyst formation also requires a kidney injury
and repair cycle to yield robust cystogenesis suggesting
that there is a developmental window, recapitulated
during cell repair that leads to a risk of cyst formation
when polycystin-1 levels are abnormal [69].
Several of the many signaling pathways altered in cystic
epithelia deserve special consideration [70]. Several potas-
sium channel genes are overexpressed in our cystic cell
lines. These potassium channel genes are KCNC4 (potas-
sium voltage-gated channel subfamily C member 4),
KCNJ12 (potassium voltage-gated channel subfamily J
member 12), KCNK3 (potassium two pore domain
channel subfamily K member 3), KCNMB4 (potassium
calcium-activated channel subfamily M regulatory beta
subunit 4), KCNQ1 (potassium voltage-gated family Q
member 1), and KCNS1 (potassium voltage-gated channel
modifier subfamily S member 1). NC-ADPKD cells have
higher-than-normal and C-ADPKD cells have lower-
than-normal expression of KCNN4 (potassium calcium-
activated channel subfamily N member 4), KCNV1 (potas-
sium voltage gated channel modifier subfamily V member
1), and KCNS3 (potassium voltage-gated channel subfam-
ily A member 3). Notably, KCNN4 is responsible for
calcium-dependent cyst fluid secretion and is thus a po-
tential therapeutic target to inhibit cyst growth [57]. Many
of these channels act to hyperpolarize the cell membrane,
and voltage-sensitive K channel membrane depolarization
induces nano-scale assembly of phosphatidyl serine, which
in turn results in nano-scale clustering sites for K-ras,
thereby promoting cell cycle progression via MAPK
downstream signaling [71, 72]. Experimental studies have
demonstrated that cyst expansion results in cell stretching
[73]. Since some K channels are stretch activated, K chan-
nel activation of proliferation could lead to feedback,
where cyst expansion driven by fluid secretion directly ac-
celerates cell-cycle progression [73–76].
Our transcriptogram analysis found significantly higher-
than-normal expression of downstream mediators of the
‘inflammasome signaling’ pathway in NC-ADPKD and
C-ADPKD samples, which may accelerate disease patho-
genesis [53, 77–80]. This signaling cascade includes
nucleotide-binding oligomerization domain receptors or
(See figure on previous page.)
Fig. 15 Comparisons of individual gene expression levels for genes selected from differentially expressed gene sets. a NOD-like receptor signaling,
b potassium ion transport, and c oxidative phosphorylation. To simplify presentation of these gene sets, where we used two or more probes in
the microarray for a single gene, we give mean values and mark the gene names with an “asterisk”. Within gene sets, we can discern changes in
individual genes responsible for differential expression of the pathways. We present data as mean ± s.e.m., **P < 0.01, *P < 0.05 (black asterisk is in
comparison to NK, gray asterisk is in comparison to NC-ADPKD). Additional file 4 provides additional information on each gene
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NOD-like receptors, which have been implicated in
renal diseases including ureteric obstruction, ischemia
reperfusion injury, glomerulonephritis, sepsis, hypoxia,
glycerol-induced renal failure, and crystal nephropathy
[53–55, 81]. Our data show that NOD-like receptor sig-
naling may also play an important role in ADPKD. NC-
ADPKD and C-ADPKD samples had higher-than-
normal (p < 0.01) expression of a number of other
inflammasome signaling genes, including: interleukin
(IL) 6, IL1β, NFκB1A, CCL2 (chemokine (C-C motif )
ligand), BIRC3, TNFAIP3, IL18, PYCARD (also called
ASC), and MAPK13.
Inflammasome signaling, a part of the innate immune
system, includes membrane receptors that recognize
conserved pathogen-associated molecular patterns
(PAMPs) on invading pathogens or host-derived danger-
associated molecular patterns (DAMPs) released in
response to stress, reactive oxygen species generation,
or cell death [78]. Both Toll-like receptors and C-type
lectin pattern recognition receptors (PRRs) can initiate
inflammasome signaling at the cell membrane [55].
Additional PRRs include the retinoic acid-inducible
gene (RIG-1)-like receptors which recognize double-
stranded RNAs (dsRNA) and NOD-like receptors
which recognize microbe-associated molecular pattern
signatures (MAMPS) and DAMPs. Other intracellular
monitors of the system include HIN-200 receptors and
RIG-1-like receptors [82–84]. Inflammasome signaling
begins with a priming phase, initiated by receptors that
signal through myeloid differentiation primary response
(MyD88) pathways and other NFκB activating pathways
such as IL-1R and the tumor necrosis factor receptor
(TNFR) [55, 85]. Priming promotes IL1β, NRLP3, and
IL18 transcription and protein synthesis and requires
interleukin 1 receptor-associated kinase (IRAK1) acti-
vation [86]. K-+efflux, adenosine tri-phosphate (ATP),
reactive oxygen species (ROS), pore-forming toxins, or
crystals [87–91] all lead to inflammasome activation.
The purinergic receptor P2X7 [78, 89, 92, 93] is an-
other inflammasome activator, which is more active
under conditions of low fluid shear stress. ADPKD
cells, lining cyst walls, are sheltered from fluid shear
normally found in tubule lumens; hence, it is likely that
in vivo P2X7 is more active [29]. Following inflamma-
some activation, NOD-like receptors such as NLRP3
form macromolecular complexes with ASC (apoptosis-
associated speck-like protein, PYCARD), an adaptor
with a caspase recruitment domain (CARD) that bridges
NLRs and caspase-1 [94]. This macromolecular complex
activates caspace-1, which enzymatically cleaves the pro-
inflammatory cytokines IL-1β and IL-18 [95]. Inflamma-
some signaling has transcriptional effects mediated via
MAPK to induce NFκB and the pro-inflammatory cyto-
kines IL-1β and IL-18 [86].
The cystic epithelial cells in our study have higher-
than-normal expression of the inflammasome adaptor
PYCARD/ASC and the signal modulators BIRC3, pre-
paring them to over-respond to inflammasome signals
[80, 95]. The cystic epithelial cells also have higher-than-
normal levels of the mRNAs encoding downstream effec-
tors of inflammasome signaling, which likely increase
expression of IL1β, IL-18, TNFα, monocyte chemotactic
protein-1 (MCP-1), and IL-6 [96–98]. While many of
these protein biomarkers correlate with disease severity in
either animal models of renal cyst disease or urine from
patients with ADPKD [99, 100], our analysis indicates that
they may also drive cyst genesis and expansion.
Intense fibrosis and loss of functional parenchyma ac-
company kidney enlargement during ADPKD disease pro-
gression [101, 102]. Our transcriptome analysis suggest
that cystic epithelial cells can excessively augment innate
inflammatory responses that may accelerate fibrosis and
stimulate a chronic inflammatory state by driving macro-
phage polarization and activation [103]. Since intracellular
levels of calcium are low in ADPKD cells [70, 104, 105]
and levels of P2X7 gene expression are lower than normal
[25], reactive oxygen species are the most likely trigger of
inflammasome assembly [88]. Even though P2X7 message
levels are lower than normal in ADPKD cells, primary
cultured cyst epithelial cells secrete high levels of ATP
[29, 106], leading to maximal stimulation of any P2X7
receptors that are present. Since P2X7 activation co-
stimulates formation of the NALP inflammasome, cystic
epithelial cells may be the primary sources of the IL18
and IL1β identified in cyst fluid [100, 107].
Recent evidence suggests that other K channels can
activate transport vesicle release in response to inflamma-
some activation, and the resultant vesicle cargo protein
composition depends on the K channel responsible for
membrane depolarization [92]. Thus, aberrant endogen-
ous K-channel expression in cystic epithelia may impair
auto regulatory responses to interleukin secretion.
We propose a scenario for the persistent inflammation
seen in ADPKD kidneys based on our transcriptogram
analysis. Our findings show higher-than-normal mRNA
expression of MCP-1 in C-ADPKD cells, which would
promote mononuclear cell infiltration into cystic kidney
parenchyma. Within the parenchyma, IL1β, IL-18, and
IL-6 can all activate infiltrated mononuclear cells. High
levels of DAMPs released by apoptotic cells, and
DAMPs such as hyaluronic acid and protein fragments
resulting from proteolytic extracellular matrix fragments
in ADPKD cystic kidneys would then further push mono-
nuclear cells towards an M2 phenotype [99, 107–111].
These M2-like monocytes would continuously secrete
transforming growth factor (TGF-β) and connective tissue
growth factor (CTGF), which would convert cells in the
interstitium to myofibroblasts [78, 102]. Other M2-like
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monocytes would stimulate epithelial cell proliferation
thereby driving cyst expansion [103]. The same signals
would stimulate Th1 cells to secrete IFN-γ, IL-13, and
Th2 cells to secrete IL-4 and IL-5 and Treg cells to secrete
IL-10 and TGF-β, exacerbating the dysregulated inflam-
matory cascade [86]. This pathogenic picture suggests that
pharmacologic interventions which attenuate the inflam-
matory cascade should delay cyst expansion and fibrosis
in ADPKD.
Conclusions
Our analysis of ADPKD provides a workflow which ap-
plies to the hierarchical analysis of any large-scale micro-
array study. We begin with transcriptogram analysis as a
method of global triage to identify intervals of altered ex-
pression in the ordered gene list, then determine which
genes in those intervals of KEGG pathways or GO terms
that are differentially expressed (e.g., ‘potassium ion trans-
port’ in Fig. 14), and finally explore the significance of al-
tered expression profiles of single genes within those
altered pathways and terms (Fig. 15). The transcripto-
grams provide crucial mechanistic context for under-
standing the significance of altered gene expression.
Methods
Cell lines and culture conditions
All cell lines derived from human kidneys under a proto-
col were approved by the Indiana University Institutional
Review Board. We immortalized all cell lines with hu-
man telomerase as previously described and maintained
them in continuous culture [25]. We grew cells with
renal epithelial growth media supplemented with 5%
fetal bovine serum (Lonza, Bazel, Switzerland and GE
Healthcare HyClone, Little Chalfont, Buckinghamshire,
UK) and maintained them at 37 °C, 5% CO2 atmosphere.
We passaged cells twice-weekly using trypsin-EDTA
(Sigma-Aldrich, St. Louis, MO). We micro-dissected the
source tissue for the NC-ADPKD and C-ADPKD cell
lines from an early stage polycystic kidney from a 36-
year-old male. We isolated NC-ADPKD cells from intact
renal tubules and C-ADPKD cells from surface cysts. All
cell lines expressed the proximal tubule markers ANPEP
(alanyl aminopeptidase, membrane), FAH (fumarylace-
toacetate hydrolase), SLC5A2 (sodium glucose trans-
porter 5A2), LRP2 (LDL receptor related protein), and
HNF1A (hepatocyte nuclear factor 1 homeobox A). They
did not express proximal marker CUBN (cubulin). All
lines expressed the cortical thick ascending limb marker
UMOD (uromodulin). No lines expressed SLC12A1 (sol-
ute carrier family 12 member 1) or KCNJ1 (potassium
voltage-gated channel subfamily J) . All cell lines expressed
the distal convoluted tubule markers KLK1 (kallikrein-1)
and KL (klotho). Only the NC-ADPKD cells expressed
SLC12A3 (solute carrier family 12 member 3). The NK
cell line expressed PVALB (parvalbumin). All cell lines
expressed the collecting duct markers, AQP2 (aquaporin
2), and SCNN1G (sodium channel epithelial 1 subunit
gamma), while no cell lines expressed FXYD2 (sodium/
potassium-transporting ATPase gamma). The gene-
expression profiles suggest that the cultured cells likely
originate from proximal tubule segments. In contrast,
the NK kidney cell line is a mixed cell population made
from whole kidney collagenase digest. Herbert et al.
have described the NK and ADPKD Q4004X cells [25].
We sequenced the HmPKD1 gene using a protocol of
Herbert et al., revealing a heterozygous truncation mu-
tation at amino acid 2556 (Q2556X) [25].
Chemicals and reagents
We purchased all buffers and inorganic chemicals from
Sigma-Aldrich (Sigma-Aldrich, St. Louis, MO). We iso-
lated total RNA from cells using TRIzol Reagent
(Thermo Fischer Scientific, Waltham, MA) according to
manufacturer’s directions. We plated cells onto Costar
membrane filter supports at a density of 50,000 cells/cm2
and grew them for 5 days to ensure confluence [25].
We labeled 200 ng of purified total RNA using the
Agilent QuickAmp labeling kit, 1-color (Agilent Tech-
nologies, Palo Alto, CA) and hybridized purified cRNA
to a custom Agilent Human Whole Genome 4x180K
array, which replicates the content of the v2 4x44k
array at least four times (AMIDID 026822). After
hybridization at 65 °C, 20 rpm for 17 h, we washed
arrays in wash buffer 1 (6XSSC (saline sodium citrate),
0.005 % TritonX-102) for 5 min at room temperature
and wash buffer 2 (0.06X SSC, 0.005 % Triton X-102)
for 5 min at 37 °C. We scanned arrays on the Agilent
High-Resolution Microarray B-series Scanner (G2505B)
and quantified the images using Agilent Feature Extrac-
tion software (version 10.7).
Microarray data preprocessing and normalization
We processed extracted feature (reporter) intensities
from each array separately by subtracting a constant to
bring the minimum intensity to 1 and then taking the
log, base 2. We mapped the transformed intensities
using a non-linear function to ensure that the cumulative
distribution profiles of the intensities were comparable
between all arrays. We present the resulting comparable
feature intensities in arbitrary units. We removed features
with low intensity from the analysis if the 90th percentile
was below the limit of detection (LoD), which we esti-
mated as the mean of a set of negative controls plus 1.96
times the standard deviation of the negative controls. We
also removed features with low range across all samples,
which we defined as having a difference between the 95th
percentile and 5th percentile of less than log 2 (1.5-fold).
We summarized the replicate probes by averaging and
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constructed a mixed-effects linear model of expression
using factors for tissue type (cysts or kidney), status
(ADPKD or NK), and cell line (NK, C-ADPKD, NC-
ADPKD, ADPKD), treating cell line as a random effect.
Volcano plotting
We averaged gene expression levels over the replicates
for each cell line after normalization and compared the
cell lines by calculating the FC. We defined FC as the
ratio between the averages and we determined P values
for each gene expressed. Volcano plots use FC as the x-
axis and the P value as the y-axis (Fig. 2). We defined
significantly changed genes as those with thresholds of
FC > 2 and P < 0.01.
Gene Set Enrichment Analysis (GSEA)
We performed gene set enrichment analysis using the
application available at the Broad Institute Gene Set
Enrichment Analysis website [26, 33]. We estimated the
signal-to-noise ratio and false discovery rates (FDR),
from 1000 gene-set permutations, due to the low num-
ber of samples in each class (n = 3). We tested the Gene
Ontology: Biological Process terms and KEGG pathways
gene sets. Since we used gene permutations, we consid-
ered gene sets to be differentially expressed if FDR < 0.05.
We calculated GSEA for NC-ADPKD versus NK, C-
ADPKD versus NK, and C-ADPKD versus C-ADPKD.
Transcriptogram analysis
Ordering the gene list
Transcriptograms give an integrated visualization of
genome-wide gene expression data by projecting expres-
sion levels onto a functionally ordered gene list to pro-
duce a genome-wide expression profile [23, 27, 34]. The
gene list ordering is based on STRING database protein-
protein interactions [34] with confidence scores over
0.800 drawn from all methods to infer associations, with
the exception of text mining. The ordering process is
performed using a Monte Carlo algorithm that mini-
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where N is the number of genes in the list and A is the
association matrix. Ai j = 1 when the products of the
genes at positions i and j in the list associate and Ai j = 0
otherwise. di j = |i − j| measures the distance between the
locations of genes i and j in the list. Minimizing F causes
associated genes to cluster in the list. Minimization
starts with a randomly ordered list of all genes whose
products have at least one association. Each step chooses
a pair of genes randomly, tentatively swaps their positions,
and calculates the change in the cost function ΔF. The
algorithm accepts the position swap whenever ΔF ≤ 0. If
ΔF > 0, the algorithm accepts the swap with probability
exp− ΔFT : T is a fluctuation amplitude that allows the con-
figuration to escape from local minima of ΔF. One
Monte-Carlo step (MCS) equals N attempted gene-pair
exchanges. The simulated annealing algorithm starts with
T large and decreases T by a small amount once every
100 MCS. The ordering algorithm produces a gene list
(Additional file 2) where the probability that any two
genes associate decays exponentially with their distance
in the list.
Visualizing KEGG pathway and GO term profiles in the
ordered list
Because STRING database interactions use KEGG path-
way maps for benchmarking and calibration [112], genes
in close proximity in the list are probably in the same
KEGG pathway. Consequently, the ordered list groups
genes by biological function. We used David’s Annota-
tional Tools [113] to obtain a list of the GO terms and
KEGG pathways that associate to intervals of the ordered
list. For each of these GO terms and KEGG pathways, we
obtain a profile by creating an N-element vector, h
!
, and
setting hi = 1, if the gene at position i in the list participates
in the specified GO term or KEGG pathway and hi = 0, if
the gene at position i in the list does not participate in the
specified GO term or KEGG pathway [113, 114]. For each
pathway or term, we obtained a profile for r = 30. A value
of 1 indicates that all genes in an interval participate in a
given GO term or KEGG pathway. We read the resulting
profiles along the ordered list as indicative of the level of
enrichment with genes of a given GO term or KEGG path-
way. Interpretation of transcriptograms is then facilitated
by comparing the enrichment profiles from regions with
significant difference in their transcriptograms.
Transcriptogram calculation
We next map the microarray data onto the ordered list.
We then smooth the raw profile to obtain a final transcrip-
togram profile, a new N − 2r − 1 element vector, k
!
using a
running average with a window of size 2r + 1 (r = 30):




where i ∈ {r + 1,N − r − 1}. The resulting profile is the
transcriptogram for the expression data. Profile peaks in
k
!
can be interpreted by comparison with the KEGG
pathways and GO terms enriched in that region of the
ordered list.
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Class comparison
We next compare transcriptograms between sample
classes. First, we produce the transcriptograms. We next
average the transcriptograms for all the samples of each
class, producing a class-average transcriptogram profile,
k
!D E
and corresponding standard error profile σ!k . To
compare a reference (R) and perturbed (P) expression
pattern, we divide the perturbed by the normal value for
each averaged transcriptogram profile element to obtain










P;R with Δi≫ 1 or ≪ 1 indicate specific
perturbed gene expression. The upper panels in Figs. 4,
5, and 6 show the relative transcriptograms.
Significance evaluation
We estimate the significance of differences between two
transcriptogram classes using a two-tailed Welch’s t test
on the class averages to obtain a P value for each list
position and by creating 500 random permutations of
the sample labels (phenotypes) to estimate the FDR. The
middle panels in Figs. 4, 5, and 6 show the P value for
each list position.
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